Australia's most trusted
source of pharma news
Posted 23 September 2021 PM
GSK's newly approved monoclonal antibody treatment Xevudy has been singled out for praise at a parliamentary hearing, which was told it's time for Australia to have "cautious optimisim" thanks not just to vaccines - but the development in Covid treatments.
Associate Professor Nick Coatsworth, who has been the federal government's public face in the fight against the pandemic, told the Senate Select hearing into COVID-19 that in his role as Executive Director of Medical Services at Canberra Hospital he spent time on the wards and had seen the drug in action.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.